How do I find recruiting Acute Myeloid Leukemia clinical trials?

Corterve aggregates actively recruiting Acute Myeloid Leukemia studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.

Are Acute Myeloid Leukemia clinical trials free to join?

Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.

Who can take part in a Acute Myeloid Leukemia clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.

Acute Myeloid Leukemia Clinical Trials

Acute Myeloid Leukemia clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for acute Myeloid Leukemia. Corterve aggregates actively recruiting Acute Myeloid Leukemia studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.

Browse all Acute Myeloid Leukemia trials Take the free assessment

Recruiting Acute Myeloid Leukemia studies

Personalized NK Cell Therapy in CBT
NCT02727803PHASE2M.D. Anderson Cancer CenterHouston, Texas
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832PHASE1AbbViePalo Alto, California
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406PHASE2National Cancer Institute (NCI)Birmingham, Alabama
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
NCT06616636PHASE1M.D. Anderson Cancer CenterTampa, Florida
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438PHASE3Stichting Hemato-Oncologie voor Volwassenen NederlandLos Angeles, California
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562PHASE3Children's Oncology GroupBirmingham, Alabama
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649PHASE2National Cancer Institute (NCI)Birmingham, Alabama
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
NCT06529731PHASE2Sawa Ito, MDSt Louis, Missouri
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT03779854PHASE2Fred Hutchinson Cancer CenterLos Angeles, California
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
NCT06287944PHASE1City of Hope Medical CenterDuarte, California
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06871410PHASE1Roswell Park Cancer InstituteBuffalo, New York
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002PHASE2, PHASE3AbbViePhoenix, Arizona

See all 238 recruiting Acute Myeloid Leukemia trials →

Acute Myeloid Leukemia trials by state

Acute Myeloid Leukemia trials by metro

Frequently asked questions

How do I find recruiting Acute Myeloid Leukemia clinical trials?: Corterve aggregates actively recruiting Acute Myeloid Leukemia studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
Are Acute Myeloid Leukemia clinical trials free to join?: Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
Who can take part in a Acute Myeloid Leukemia clinical trial?: Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.